Nektar Therapeutics traded at $3.14 this Friday September 23rd, decreasing $0.08 or 2.48 percent since the previous trading session. Looking back, over the last four weeks, Nektar Therapeutics lost 33.47 percent. Over the last 12 months, its price fell by 83.04 percent. Looking ahead, we forecast Nektar Therapeutics to be priced at 3.05 by the end of this quarter and at 2.78 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
3.14
Daily Change
-2.48%
Yearly
-83.04%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Takeda 3,740.00 -49.00 -1.29% -0.82%
Eisai 5,733.00 -104.00 -1.78% -32.99%
Agios Pharmaceuticals 28.99 -0.63 -2.13% -38.99%
ALKERMES 22.32 -0.15 -0.67% -30.42%
Amgen 226.97 -0.78 -0.34% 6.25%
Astrazeneca 54.58 -1.73 -3.07% -9.56%
Baxter International 55.41 0.04 0.07% -31.47%
BioCryst Pharmaceuticals 12.36 -0.34 -2.68% -17.16%
Biogen 197.78 -2.84 -1.42% -32.20%
Bluebird Bio 5.62 -0.35 -5.86% -69.52%
Bristol-Myers Squibb 70.71 -0.58 -0.81% 17.40%
Cara Therapeutics 8.48 -0.32 -3.64% -46.77%
Dr.Reddys Laboratories 4,147.75 8.55 0.21% -13.44%
Esperion Therapeutics 6.70 -0.26 -3.74% -42.14%
Exelixis 16.28 -0.29 -1.75% -20.00%
Gilead Sciences 62.86 -0.91 -1.43% -11.70%
GlaxoSmithKline 1,313.20 17.20 1.33% -5.39%
Halozyme Therapeutics 38.82 0.08 0.21% -3.65%
Immunogen 4.58 -0.12 -2.55% -22.37%
Incyte Corp 66.89 -0.52 -0.77% -3.06%
Ionis Pharmaceuticals 43.23 -1.74 -3.87% 19.42%
Ironwood Pharmaceuticals 10.18 -0.25 -2.40% -24.31%
Karyopharm Therapeutics 4.40 -0.21 -4.56% -29.71%
Eli Lilly 311.46 0.59 0.19% 34.44%
MacroGenics 3.04 0.03 1.00% -84.60%
Merck & Co 86.78 -0.73 -0.83% 17.89%
Mirati Therapeutics 68.18 -1.76 -2.52% -59.02%
Neurocrine Biosciences 103.50 0.16 0.15% 8.96%
Nektar Therapeutics 3.14 -0.08 -2.48% -83.04%
Novartis 74.36 -0.69 -0.92% -3.38%
Pfizer 44.08 -0.49 -1.10% 0.32%
Roche Holding 309.30 -2.30 -0.74% -9.14%
Seattle Genetics 139.20 -1.35 -0.96% -13.72%
Sarepta Therapeutics 108.19 -2.68 -2.42% 19.45%
Teva Pharmaceutical Industries Ltd 2,804.00 -124.00 -4.24% -1.72%
Xencor 24.96 -0.80 -3.11% -26.33%

Indexes Price Day Year
USND 10868 -198.88 -1.80% -27.78%
US2000 1680 -42.72 -2.48% -25.29%
US400 2239 -48.73 -2.13% -17.04%

Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company. The Company discovers and develops medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes treatments for cancer and autoimmune disease. It has research and development (R&D) pipeline of medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. It leverages its chemistry platform to discover and design new drug candidates. These drug candidates utilize its polymer conjugate technology platforms, which are designed to enable the development of new molecular entities. Its R&D pipeline includes Bempegaldesleukin (NKTR-214), NKTR-358, NKTR-262 and NKTR-255. It develops medicines designed to modulate the activity of key immune cells, such as cytotoxic T cells and Natural Killer (NK) cells, to increase their numbers and improve their function to recognize and attack cancer cells directly or indirectly.